Gapping down
In reaction to earnings/guidance:
- DRVN -13.4%, LBRT -10.1%, HOOD -9%, FBC -6.7%, RRC -6.3%, DB -5.9%, TXN -4.8%, ALKS -4.5%, AGYS -4.4%, NYCB -4.4%, NCR -4.2%, EQNR -3.9%, NBR -3.5%, UMBF -3.4%, NOV -3.1%, CSGP -3%, QS -2.9%, VBTX -2.9%, V -2.4% (also increases dividend), DT -2.2%, HA -1.9%, WAB -1.9%, BSX -1.6%, DTE -1.1%, FISV -1%, ROL -0.9%, WSBC -0.8%, CME -0.8%, IP -0.7%, AMD -0.6%
Other news:
- CRTX -68% (reports data from Phase 2/3 GAIN trial; co-primary endpoints were not met in overall population)
- ANGN -52.2% (Angion Biomedica and Viror Pharma report phase-III trial of ANG-3777 did not meet primary endpoint)
- DBVT -22.2% (provides regulatory updates from the FDA and EMA for Viaskin Peanut)
- VALN -9.1% (stock offering)
- FDMT -5% (stock offering)
- PHAT -1.5% (stock offering)
- CLAR -1.2% (prices offering of 2.75 mln shares of common stock for gross proceeds of $74.25 mln)
Analyst comments:
- NET -3.5% (downgraded to Hold from Buy at Jefferies)
- ECL -1.1% (downgraded to Underweight from Neutral at JP Morgan)